Unmask Cancer,
Elicit Immune Response

Read more

Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases

A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key N-glycosylation mechanism responsible for suppressing the immune response.

Our first generation of N-glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.

News

07/06/2022

Phost'in Therapeutics announces approval of French and Italian Health Agency for a first European clinical trial application in patients with advanced solid tumors, in collaboration with Foundation Gianni Bonnadona

Montpellier, France – June 2022, 07th
Read more
09/03/2022

Phost'in Therapeutics joins TechShare 2022, Euronext's paneuropean Pre-IPO training program

Montpellier, France – Mars 2022, 09th
Read more
17/06/2020

Phost'in Therapeutics strengthens management with appointment of veteran lifescience executives Dr. Alain Herrera and Pr. Bernard Pau

Montpellier, France – June 2020, 17th
Read more
25/04/2020

€10M Series A Boosts Cancer Immunotherapy Hitting Tumor Sugar Coating

LABIOTECH.eu – April 2020, 22nd
Read more